Replies to post #100490 on Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

You are wrong. Although the clinical data from ADXS is very limited, the data from NTGN is much larger albeit it's still Phase 1. The point was the Neon's therapies are very similar to what's Advaxis is doing, and thus, it should provide some clues whether the Advaxis therapies would succeed or not. This was the reason we eagerly anticipated Neon's IPO, and then start of the neoantigens trial. Now that they have the data, we can project where we are expectations should be for NEO and HOT. There should be strong correlation between these two companies as there was a link between ADRO and ADXS. Remember, how that ended? ADRO was first to dump their Lm platform, then, three years later, it was us who did the same. Also, recall that ADRO's platform was considered a "subpar" platform to Advaxis' as they stole from us. That was a great lesson.